A360
Key Takeaways✦ Atlas AI
01
The WHO has prequalified the first malaria treatment specifically for newborns and infants, addressing a critical gap in safe and effective medication for approximately 30 million vulnerable babies born annually in malaria-prone areas.
02
New rapid diagnostic tests (RDTs) targeting a different parasite protein have been prequalified to combat the rising issue of gene deletions that render older HRP2-based tests ineffective, significantly improving diagnostic accuracy in affected regions.
03
These advancements in treatment and diagnostics are crucial steps in the fight against malaria, especially as global cases and deaths increased in 2024, highlighting the urgent need for innovative solutions amidst growing resistance and funding challenges.
Atlas AI
WHO prequalification indicates the products meet international standards for quality, safety, and efficacy, and it enables procurement by public-sector buyers. Officials said the new infant-focused medicine is intended to close a long-standing treatment gap in malaria-endemic settings.
Until now, infants in this weight range were typically given malaria formulations developed for older children. WHO said that practice increased the risk of dosing mistakes and potential adverse effects, because the products were not tailored to newborns and very small infants. The newly prequalified treatment is aimed at reducing those risks by providing an option specifically made for babies weighing 2-5 kilograms.
WHO linked the significance of the new medicine to the scale of need in malaria-affected regions. Officials said about 30 million babies are born each year in malaria-endemic areas, and the absence of a dedicated treatment for the smallest infants has been a persistent gap in care. The prequalification is intended to help countries and partners purchase the medicine through public channels where WHO standards are commonly used as a benchmark.
In parallel, WHO said it has prequalified three new malaria RDTs that detect a different parasite protein, pf-LDH. The move addresses a growing problem in which some malaria strains have gene deletions that undermine older tests based on the HRP2 target. Reports cited by WHO indicate that in some regions, HRP2-based tests missed up to 80% of cases because of these deletions, raising the risk that infected patients are not correctly identified and treated.
WHO said the newly prequalified pf-LDH tests offer a reliable alternative where HRP2-based diagnostics are failing. The agency . Officials framed the guidance as a practical threshold for switching tools in places where diagnostic performance has been compromised.
The announcements come as WHO reported that global malaria cases and deaths increased in 2024, with an estimated 282 million cases and 610,000 deaths. WHO cited several pressures contributing to setbacks, including drug and insecticide resistance, diagnostic failures, and reduced international development assistance. Officials said these challenges complicate efforts to control transmission and protect vulnerable groups, including newborns and infants.
